RxDoctor Payments Data

Srikant Duggirala, MD

Clinical Cardiac Electrophysiology · Covina, CANPI 1952507923

Payments from drug & device makers

$44,038in general payments, 2019–2025

Across 1,045 payments — averaging $42.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14K
  • Abbott$8K
  • Medtronic$7K
  • Boston Scientific$5K
  • Atricure, Inc.$2K
  • Novartis$2K
  • plus $6K from 32 others

What the payments were for

  • Consulting fees$3,8449%
  • Speaking & faculty fees$13,05030%
  • Travel & lodging$4,78711%
  • Food & beverage$22,16050%
  • Education$1970%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,038 in reported general payments places this provider in the 55th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$663,030
Medicare patients
936
Services billed
5,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,428$1,208,100
XareltoRivaroxaban244$240,242
MultaqDronedarone Hcl85$113,602
EntrestoSacubitril/Valsartan67$50,691
FarxigaDapagliflozin Propanediol51$47,658
JardianceEmpagliflozin33$25,602
Metoprolol Succinate839$14,032
Flecainide Acetate247$10,630
Amiodarone Hcl321$8,141
Diltiazem 12hr ErDiltiazem Hcl26$7,041
Dofetilide13$3,981
Diltiazem 24hr Er (Cd)Diltiazem Hcl84$2,745
Carvedilol309$2,207
Atorvastatin Calcium304$1,858
Amlodipine Besylate305$1,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,297$1,208,1001,428 claims
Johnson & JohnsonXarelto$639$240,242244 claims
Sanofi-aventis U.S. LLCMultaq$431$113,60285 claims
NovartisEntresto$1,768$50,69167 claims
AstraZenecaFarxiga$503$47,65851 claims
Boehringer IngelheimJardiance$265$25,60233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →